Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 52.17 USD 2.5% Market Closed
Market Cap: 5.5B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Corcept Therapeutics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Additional Paid In Capital
$806.3m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
10%
Johnson & Johnson
NYSE:JNJ
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Additional Paid In Capital
$45.9B
CAGR 3-Years
1%
CAGR 5-Years
83%
CAGR 10-Years
41%
Pfizer Inc
NYSE:PFE
Additional Paid In Capital
$93.2B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Additional Paid In Capital
$44.5B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Additional Paid In Capital
$7.3B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
No Stocks Found

Corcept Therapeutics Inc
Glance View

Market Cap
5.4B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs. The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.

CORT Intrinsic Value
70.06 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Corcept Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
806.3m USD

Based on the financial report for Sep 30, 2024, Corcept Therapeutics Inc's Additional Paid In Capital amounts to 806.3m USD.

What is Corcept Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
10%

Over the last year, the Additional Paid In Capital growth was 12%. The average annual Additional Paid In Capital growth rates for Corcept Therapeutics Inc have been 12% over the past three years , 13% over the past five years , and 10% over the past ten years .

Back to Top